Balyasny Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Balyasny Asset Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-32,105	Closed	-$124K	–	2268
2018 Q2	$124K	Buy	32,105 +10,930	+52%	+$72.6K	﹤0.01%	1694
2018 Q1	$134K	Buy	21,175 +2,796	+15%	+$23.1K	﹤0.01%	1808
2017 Q4	$148K	Buy	+18,379	New	+$171K	﹤0.01%	1947
2017 Q3	–	Sell	-1,627	Closed	-$16K	–	2221
2017 Q2	$16K	Buy	+1,627	New	+$33.2K	﹤0.01%	1429
2017 Q1	–	Sell	-31,457	Closed	-$1.01M	–	1892
2016 Q4	$1.01M	Sell	31,457 -92,466	-75%	-$3.94M	0.01%	1021
2016 Q3	$6.19M	Buy	123,923 +119,708	+2,840%	+$4.97M	0.04%	468
2016 Q2	$179K	Buy	+4,215	New	+$230K	﹤0.01%	1051
2015 Q3	–	Sell	-152,649	Closed	-$14.9M	–	1532
2015 Q2	$14.9M	Buy	152,649 +24,262	+19%	+$2.31M	0.09%	283
2015 Q1	$12M	Buy	+128,387	New	+$10.9M	0.1%	303
2014 Q3	–	Sell	-97,206	Closed	-$5.58M	–	931
2014 Q2	$5.58M	Buy	97,206 +56,653	+140%	+$2.88M	0.06%	353
2014 Q1	$1.61M	Sell	40,553 -96,330	-70%	-$4.12M	0.02%	492
2013 Q4	$5.74M	Buy	+136,883	New	+$3.97M	0.07%	292

Other funds holding MACK

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Balyasny Asset Management's MACK Position: Q3 2018 in Review

Balyasny Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2018, closing a stake of 32,105 shares — an estimated $124K sold.

Balyasny Asset Management first reported a position in MACK in Q4 2013 and held it in 12 quarters. The position peaked at $14.9M in Q2 2015. 63 funds tracked by Wall St. Rank hold MACK as of Q3 2018.

Balyasny Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Balyasny Asset Management sold 32,105 Merrimack Pharmaceuticals, Inc. shares in Q3 2018, an estimated $124K.
Balyasny Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2013 and held it in 12 quarters.
Balyasny Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $14.9M in Q2 2015.
63 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2018.

Based on Balyasny Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.